6/30/23, 2:15 AM TAME Pathway Feedback Search Clinical Topics Home Studies TAME TAME Disease Disease Generalized anxiety disorder Social anxiety disorder Trial question Is mindfulness-based stress reduction noninferior to escitalopram in adults with anxiety disorders? Study design Multi-center Open label RCT Population Characteristics of study participants 75.0% female N = 208 25.0% male 208 patients (156 female, 52 male) Inclusion criteria: adults with a diagnosed anxiety disorder Key exclusion criteria: comorbid psychiatric disorder other than anxiety or depression; serious medical condition that may result in surgery/hospitalization; history of head trauma causing loss of consciousness; or ongoing cognitive impairment Interventions N=136 mindfulness-based stress reduction (mindfulness meditation group class taught in person for 8 weeks) N=140 escitalopram (flexibly dosed from 10-20 mg daily PO) Primary outcome https://web.pathway.md/studies/reckX7YnHorv6BQYf 1/2 6/30/23, 2:15 AM TAME Pathway Anxiety levels reduction as assessed with clinical global impression of severity scale 1.4 1.43 1.35 1.1 0.7 Difference not exceeding nonferiority margin 0.4 0.0 Mindfulness-based stress reduction Escitalopram Difference not exceeding nonferiority margin in anxiety levels reduction as assessed with clinical global impression of severity scale (1.35 vs. 1.43; AD -0.07, 95% CI 0.23 to 0.38) Safety outcomes Significant difference in 1 study-related adverse event (15.4% vs. 78.6%). Conclusion In adults with a diagnosed anxiety disorder, mindfulness-based stress reduction was noninferior to escitalopram with respect to anxiety levels reduction as assessed with clinical global impression of severity scale. Reference Elizabeth A Hoge, Eric Bui, Mihriye Mete et al. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Nov 9;e223679. Open reference URL https://web.pathway.md/studies/reckX7YnHorv6BQYf 2/2